Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03051464 · ClinicalTrials.gov registry record · Phase 2
No Surgery Trial / Two Dose-escalation Strategies
A Phase 2 study of Stage II Rectal Cancer, sponsored by Sir Mortimer B. Davis - Jewish General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
- 4
- Study locations
NCT03051464: Recruiting Phase 2 study of Stage II Rectal Cancer, sponsored by Sir Mortimer B. Davis - Jewish General Hospital.
NCT03051464 is a Phase 2 study of Stage II Rectal Cancer that is actively recruiting participants, run by Sir Mortimer B. Davis - Jewish General Hospital. The registered enrollment target is 131 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03051464, a Phase 2 study of Stage II Rectal Cancer, is actively recruiting participants, sponsored by Sir Mortimer B. Davis - Jewish General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
- 4
- Study locations
Study Summary
A randomized study of 131 patients. Patients with a clinical T2-3 N0 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy compared to arm B: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions).
Primary Outcome
Time from date of randomization to either TME or death in the intention to treat population
Conditions Studied
Interventions
- PROCEDURE Complete responders and Non-complete responders
- RADIATION Chemoradiation + EBRT Boost
- RADIATION Chemoradiation + HDRBT Boost
Study Locations (4)
Quebec
- Le Centre Hospitalier de l'Université de Montreal - Montreal
- Jewish General Hospital - Montreal
- Centre hospitalier universitaire de Québec - Québec
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2017-04-25 |
| Est. Completion | 2030-01 |
| Phase | Phase 2 |
What NCT03051464 shows while recruiting
NCT03051464 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Stage II Rectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Complete responders and Non-complete responders is the first listed.
NCT03051464 reports a single indexed study location in Quebec, Texas.
Frequently Asked Questions
What is clinical trial NCT03051464 about?
NCT03051464 is a clinical study titled "No Surgery Trial / Two Dose-escalation Strategies". A randomized study of 131 patients. Patients with a clinical T2-3 N0 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy compared to arm B: standard chemoradiation (45 Gy in 25 with...
What is the current status of trial NCT03051464?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2017-04-25. Estimated completion is 2030-01.
What conditions does trial NCT03051464 study?
This clinical trial studies the following conditions: Stage II Rectal Cancer.
What interventions are being tested in trial NCT03051464?
The interventions under investigation include: Complete responders and Non-complete responders (PROCEDURE), Chemoradiation + EBRT Boost (RADIATION), Chemoradiation + HDRBT Boost (RADIATION).
Who is sponsoring clinical trial NCT03051464?
This trial is sponsored by Sir Mortimer B. Davis - Jewish General Hospital, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03051464 being conducted?
This trial has 4 study locations across Texas, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage II Rectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03051464's enrollment target sits among peer trials
131 541st of 2000 higher than 1,459 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04301843 · 131 participants · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- NCT04748549 · 131 participants · NA
Intraoperative VR for Older Patients Undergoing TKA
- NCT05951179 · 131 participants · Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
- NCT07246863 · 131 participants · Phase 2
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI